MedTrace Logo

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

NCT02376452 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2015-03-03

No results posted yet for this study

Summary

This study is designed to compare the efficacy and safety of two-weekly RAILIRI regimen with FOLFIRI regimen in the treatment of advanced colorectal cancer patients in the second-line setting.

Conditions

  • Colorectal Carcinoma

Interventions

DRUG

Raltitrexed

2mg/m2 iv gtt, d1

DRUG

Irinotecan

180 mg/m2 iv gtt, d1

DRUG

5-fluorouracil

5-FU 400mg/m2 iv, 2400mg/m2 civ 46h

DRUG

Leucovorin

400mg/m2 iv gtt,d1

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Wen Zhang · Medical Oncology, Fudan University Shanghai Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-12-31
Completion
2016-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02376452 on ClinicalTrials.gov